Reduced Blood-brain Barrier Penetration of Sarecycline Relative to Minocycline in Rats Corresponds with Lipophilicity and Low Vestibular Side Effects

Linda Stein-Gold; Angela Moore; S. Ken Tanaka; Jodi Johnson; Ayman Grada

doi:10.25251/skin.4.supp.107

Linda Stein-Gold

Henry Ford Health System, Detroit, Michigan

Angela Moore

Baylor University Medical Center, Dallas, Texas; Arlington Research Center, Arlington, Texas

S. Ken Tanaka

Paratek Pharmaceuticals, Inc. King of Prussia, Pennsylvania

Jodi Johnson

Department of Dermatology and Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL

Ayman Grada

R&D and Medical Affairs, Almirall (US), Exton, Pennsylvania

Keywords

Pharmacology, Sarecycline, Blood-Brain Barrier, Vestibular Side Effects

Abstract

Abstract not available.

References

1. Pariser DM, Green LJ, Lain EL, et al. Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study. Journal of Clinical and Aesthetic Dermatology. 2019;12(11):E53-E62.

Poster PDF

Published

Oct 27, 2020

DOI https://doi.org/10.25251/skin.4.supp.107

How to Cite

Stein-Gold, L., Moore, A., Tanaka, S. K., Johnson, J., & Grada, A. (2020). Reduced Blood-brain Barrier Penetration of Sarecycline Relative to Minocycline in Rats Corresponds with Lipophilicity and Low Vestibular Side Effects. SKIN The Journal of Cutaneous Medicine, 4(6), s107. https://doi.org/10.25251/skin.4.supp.107

Issue

Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

Section

Dermatopharmacology

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Angela Moore, Suzanne Bruce, Neil Sadick, Eduardo Tschen, Philip Werschler, Sunil Dhawan, Douglas Farsha, Michael Gold, Scott Guenthner, Steve Kempers, Leon Kircik, Jennifer Parish, Marta Rendon, Phoebe Rich, Linda Stein-Gold, Stephen Tyring, Robert Weiss, Adnan Nasir, Carsten Schmitz, Terry Boodhoo, Alexandre Kaoukhov, David Berk, Fran Cook-Bolden, Ayman Grada, Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Brian Berman, April Armstrong , Mark Lebwohl, Ayman Grada, Neal Bhatia, Vishal Patel, Darrell Rigel, James Del Rosso, Todd Schlesinger, Leon Kircik, Raidah Salem, Ismail Kasujee, Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler, Mark Lebwohl, Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Jerry Bagel, Linda Stein Gold, James Del Rosso, Neal Bhatia, Sandy Johnson , Paul Yamauchi, Angela Moore, Anna Tallman, Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Matthew Zirwas, Zoe Draelos, Janet Dubois, Leon Kircik, Angela Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence Green, Scott Guenthner, Laura Ferris, Seth Forman, Steven Kempers, Edward Lain, Charles Lynde, David Pariser, David Pariser, Darryl Toth, paul Yamauchi, Patrick Burnett, David Berk, A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Brian Berman, Todd Schlesinger, Neal Bhatia, Ayman Grada, Laura Padulles, Francisco Hernandez, david Cutler, Mark Lebwohl, Complete clearance of actinic keratosis with tirbanibulin ointment 1% is not correlated with the severity of local skin reactions , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Laura Padulles, Francisco Hernandez, David Cutler, Mark Lebwohl, Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Angela Moore, Javier Alonso-Llamazares, Neal Bhatia, Alim Devani, Michael Bukhalo, Zoe Draelos, Melinda Gooderham, Steve Kempers, Leon Kircik, Kim Papp, David Pariser, Marina Sankeva, Rodney Sinclair, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Andrew Blauvelt, Javier Alonso-Llamazares, Neal Bhatia, Zoe Draelos, Janet DuBois, Seth Forman, Melinda Gooderham, Scott Guenthner, Adelaide Hebert, Edward Lain, Angela Moore, Kim Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David Berk, David Chu, Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

1 2 3 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)